Top

Published in:

01-02-2009 | Report

Gender and Other Psychosocial Factors as Predictors of Adherence to Highly Active Antiretroviral Therapy (HAART) in Adults with Comorbid HIV/AIDS, Psychiatric and Substance-related Disorder

Authors: Allison J. Applebaum, Mark A. Richardson, Stephen M. Brady, Deborah J. Brief, Terence M. Keane

Published in: AIDS and Behavior | Issue 1/2009

Abstract

This study assessed adherence to HAART among 67 HIV-infected adults, and the degree to which gender and psychological factors—including depression, drug and alcohol use, quality of life, and medication side effects—influenced adherence. Although overall adherence was greater than rates reported in similar studies, no significant difference in adherence was observed between men and women in the present sample. Medication side effects were a significant predictor of non-adherence in the sample at large and among women in particular, while alcohol dependence was a significant predictor of non-adherence only in women. Possible explanations are explored.

Berg, K., Demas, P., Howard, A., Schoenbaum, E., Gourevitch, M., & Arnsten, J. (2004). Gender differences in factors associated with adherence to antiretroviral therapy. Journal of General Internal Medicine, 19, 1111–1117. doi:10.1111/j.1525-1497.2004.30445.x.PubMedCrossRef

Carrieri, M., Spire, B., Duran, S., Katlama, C., Peyramond, D., Francois, C., et al. (2003). Health-related quality of life after 1 year of highly active antiretroviral therapy. Journal of Acquired Immune Deficiency Syndromes, 32, 38–47.PubMed

Chesney, M. A., Ickovics, J. R., Chambers, D. B., Gifford, A. L., Neidig, J., Zwicks, B., et al. (2000). Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: The AACTG Adherence Instruments. AIDS Care, 12, 255–266. doi:10.1080/09540120050042891.PubMedCrossRef

Cook, J., Cohen, M., Burke, J., Grey, D., Anastos, K., Kirstein, L., et al. (2002). Effects of depressive symptoms and mental health quality of life on use of highly active antiretroviral therapy among HIV-seropositive women. Journal of Acquired Immune Deficiency Syndromes, 30, 401–409. doi:10.1097/01.qai.0000018280.16783.fe.PubMed

Cook, J., Grey, D., Burke-Miller, J., Cohen, M., Vlahov, D., Kapadia, F., et al. (2007). Illicit drug use, depression and their association with highly active antiretroviral therapy in HIV-positive women. Drug and Alcohol Dependence, 89, 74–81. doi:10.1016/j.drugalcdep. 2006.12.002.PubMedCrossRef

Haug, N., Sorensen, J., Lllo, N., Gruber, V., Delucchi, K., & Hall, S. (2005). Gender differences among HIV- positive methadone maintenance patients enrolled in a medication adherence trial. AIDS Care, 17, 1022–1029. doi:10.1080/09540120500100882.PubMedCrossRef

HIV/AIDS Treatment Adherence, Health Outcomes and Cost Study Group. (2004). The HIV/AIDS Treatment Adherence. Health Outcomes and Cost Study: Conceptual foundations and overview. AIDS Care, 16(Suppl. 1), S6–S21. doi:10.1080/09540120412331315312.

Johnston, R., & Mann, T. (2000). Barriers to antiretroviral medication adherence in HIV infected women. AIDS Care, 12, 377–386. doi:10.1080/09540120050123774.CrossRef

Shor-Posner, G., Lecusay, R., Miguez-Burbano, M., Quesada, J., Rodriguez, A., Ruiz, P., et al. (2000). Quality of life measures in the Miami HIV-infected drug abusers cohort: Relationship to gender and disease status. Journal of Substance Abuse, 11, 395–404. doi:10.1016/S0899-3289(00)00035-3.PubMedCrossRef

Turner, B., Laine, C., Cosler, L., & Hauch, W. (2003). Relationship of gender, depression, and health care delivery with antiretroviral adherence in HIV-infected drug users. Journal of General Internal Medicine, 18, 248–257. doi:10.1046/j.1525-1497.2003.20122.x.PubMedCrossRef

Uldall, K., Palmer, N., Whetten, K., & HIV/AIDS Treatment Adherence, Health Outcomes and Cost Study Group. (2004). Adherence in people living with HIV/AIDS, mental illness, and chemical dependency: A review of the literature. AIDS Care, 16(Suppl. 1), S71–S96. doi:10.1080/09540120412331315277.PubMedCrossRef

Ware, J., Kosinski, M., Bayliss, M., McHorney, C., Rogers, W., & Raczek, A. (1995). Comparison on methods for the scoring and statistical analysis of SF-36 Health Profile and Summary Measures. Summary of results from the Medical Outcomes Study. Medical Care, 33, AS264–AS279. doi:10.1097/00005650-199501001-00005.PubMedCrossRef

Title: Gender and Other Psychosocial Factors as Predictors of Adherence to Highly Active Antiretroviral Therapy (HAART) in Adults with Comorbid HIV/AIDS, Psychiatric and Substance-related Disorder
Authors: Allison J. Applebaum
Mark A. Richardson
Stephen M. Brady
Deborah J. Brief
Terence M. Keane
Publication date: 01-02-2009
Publisher: Springer US
Published in: AIDS and Behavior / Issue 1/2009
Print ISSN: 1090-7165
Electronic ISSN: 1573-3254
DOI: https://doi.org/10.1007/s10461-008-9441-x

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2009

The Information–Motivation–Behavioral Skills Model of ART Adherence in a Deep South HIV+ Clinic Sample

Adherence to Anti Retroviral Therapy (ART) During Muslim Ramadan Fasting

African-American Female Adolescents Who Engage in Oral, Vaginal and Anal Sex: “Doing It All” as a Significant Marker for Risk of Sexually Transmitted Infection

Assessing Social Preparedness for Antiretroviral Therapy in a Generalized AIDS Epidemic: A Diffusion of Innovations Approach

The Role of Host Genetics in the Susceptibility for HIV-associated Neurocognitive Disorders

Factors Associated with HIV Viral Load in a Respondent Driven Sample in Los Angeles

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials